SE0100733D0 - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors

Info

Publication number
SE0100733D0
SE0100733D0 SE0100733A SE0100733A SE0100733D0 SE 0100733 D0 SE0100733 D0 SE 0100733D0 SE 0100733 A SE0100733 A SE 0100733A SE 0100733 A SE0100733 A SE 0100733A SE 0100733 D0 SE0100733 D0 SE 0100733D0
Authority
SE
Sweden
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
compounds
relates
Prior art date
Application number
SE0100733A
Other languages
English (en)
Swedish (sv)
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Priority to SE0100733A priority Critical patent/SE0100733D0/xx
Publication of SE0100733D0 publication Critical patent/SE0100733D0/xx
Priority to TW091103297A priority patent/TWI228990B/zh
Priority to MYPI20020739A priority patent/MY137083A/en
Priority to PL364414A priority patent/PL207392B1/pl
Priority to KR1020037011616A priority patent/KR100884494B1/ko
Priority to CN200610082490XA priority patent/CN101081843B/zh
Priority to MXPA03008040A priority patent/MXPA03008040A/es
Priority to JP2002569836A priority patent/JP4463478B2/ja
Priority to DK02748329.6T priority patent/DK1373261T3/da
Priority to AT02748329T priority patent/ATE508128T1/de
Priority to BR0207886-4A priority patent/BR0207886A/pt
Priority to CA2438524A priority patent/CA2438524C/en
Priority to EP02748329A priority patent/EP1373261B1/en
Priority to IL15754302A priority patent/IL157543A0/xx
Priority to CNB02806027XA priority patent/CN1264839C/zh
Priority to PCT/EP2002/002328 priority patent/WO2002070516A2/en
Priority to ES02748329T priority patent/ES2364926T3/es
Priority to RU2003129513/04A priority patent/RU2281284C2/ru
Priority to AU2002308231A priority patent/AU2002308231B2/en
Priority to DE60239924T priority patent/DE60239924D1/de
Priority to US10/092,752 priority patent/US6716850B2/en
Priority to ARP020100797A priority patent/AR035941A1/es
Priority to US10/377,057 priority patent/US6894177B2/en
Priority to IL157543A priority patent/IL157543A/en
Priority to HK04106555A priority patent/HK1063784A1/xx
Priority to US11/071,675 priority patent/US7405310B2/en
Priority to HK08105844.9A priority patent/HK1111155A1/xx
Priority to JP2009028717A priority patent/JP2009102436A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C245/18—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
SE0100733A 2001-03-05 2001-03-05 Non-nucleoside reverse transcriptase inhibitors SE0100733D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0100733A SE0100733D0 (sv) 2001-03-05 2001-03-05 Non-nucleoside reverse transcriptase inhibitors
TW091103297A TWI228990B (en) 2001-03-05 2002-02-25 Non-nucleoside reverse transcriptase inhibitors
MYPI20020739A MY137083A (en) 2001-03-05 2002-03-01 Non-nucleoside reverse transcriptase inhibitors
DE60239924T DE60239924D1 (de) 2001-03-05 2002-03-04 Cyclopropaheterocyclen als nicht-nukleosidische hemmer der reversen transkriptase
EP02748329A EP1373261B1 (en) 2001-03-05 2002-03-04 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
ES02748329T ES2364926T3 (es) 2001-03-05 2002-03-04 Ciclopropaheterociclos como inhibidores no nucleosidos de la transcriptasa inversa.
CN200610082490XA CN101081843B (zh) 2001-03-05 2002-03-04 非核苷逆转录酶抑制剂
MXPA03008040A MXPA03008040A (es) 2001-03-05 2002-03-04 Ciclopropaheterociclos como inhibidores de transcriptasa inversa de no-nucleosido.
JP2002569836A JP4463478B2 (ja) 2001-03-05 2002-03-04 非ヌクレオシド逆転写酵素インヒビターとしてのシクロプロパヘテロ環
DK02748329.6T DK1373261T3 (da) 2001-03-05 2002-03-04 Cyklopropaheterocykler som non-nukleotid revers transkriptase-hæmmer
AT02748329T ATE508128T1 (de) 2001-03-05 2002-03-04 Cyclopropaheterocyclen als nicht-nukleosidische hemmer der reversen transkriptase
BR0207886-4A BR0207886A (pt) 2001-03-05 2002-03-04 Ciclopropa-heterociclos como inibidores de transcriptase reversa não-nucleosìdeos
CA2438524A CA2438524C (en) 2001-03-05 2002-03-04 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
PL364414A PL207392B1 (pl) 2001-03-05 2002-03-04 Związek (-) -cis-1-(5-cyjanopirydyn-2-ylo)-3-(4,7-difluoro-1,1a,2,7b-tetrahydrocyklopropa [c] chromen-1-ylo) mocznik, jego zastosowanie oraz kompozycja farmaceutyczna
IL15754302A IL157543A0 (en) 2001-03-05 2002-03-04 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
CNB02806027XA CN1264839C (zh) 2001-03-05 2002-03-04 非核苷逆转录酶抑制剂
PCT/EP2002/002328 WO2002070516A2 (en) 2001-03-05 2002-03-04 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
KR1020037011616A KR100884494B1 (ko) 2001-03-05 2002-03-04 비-누클레오시드 역전사효소 억제제로서의 사이클로프로파헤테로사이클 및 이를 포함하는 약제학적 조성물
RU2003129513/04A RU2281284C2 (ru) 2001-03-05 2002-03-04 Ненуклеозидные ингибиторы обратной транскриптазы, фармацевтическая композиция, содержащая их, их применение при изготовлении лекарственных средств для лечения вич-1, промежуточные для их получения
AU2002308231A AU2002308231B2 (en) 2001-03-05 2002-03-04 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
ARP020100797A AR035941A1 (es) 2001-03-05 2002-03-05 Derivados de n-(fenil-heterociclil-ciclopropil) y n´-heterociclil urea y tiourea,composicion farmaceutica su uso en la fabricacion de medicamentos para el tratamiento de pacientes infectados o expuestos al hiv-1 y compuestos intermediarios que se usan en su preparacion
US10/092,752 US6716850B2 (en) 2001-03-05 2002-03-05 Non-nucleoside reverse transcriptase inhibitors
US10/377,057 US6894177B2 (en) 2001-03-05 2003-02-28 Intermediate compounds of non-nucleoside reverse transcriptase inhibitors
IL157543A IL157543A (en) 2001-03-05 2003-08-21 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
HK04106555A HK1063784A1 (en) 2001-03-05 2004-08-31 Non-nucleoside reverse transcriptase inhibitors
US11/071,675 US7405310B2 (en) 2001-03-05 2005-03-02 Non-nucleoside reverse transcriptase inhibitors
HK08105844.9A HK1111155A1 (en) 2001-03-05 2008-05-26 Non-nucleoside reverse transcriptase inhibitors
JP2009028717A JP2009102436A (ja) 2001-03-05 2009-02-10 非ヌクレオシド逆転写酵素インヒビターとしてのシクロプロパヘテロ環

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100733A SE0100733D0 (sv) 2001-03-05 2001-03-05 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
SE0100733D0 true SE0100733D0 (sv) 2001-03-05

Family

ID=20283208

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100733A SE0100733D0 (sv) 2001-03-05 2001-03-05 Non-nucleoside reverse transcriptase inhibitors

Country Status (22)

Country Link
US (3) US6716850B2 (xx)
EP (1) EP1373261B1 (xx)
JP (2) JP4463478B2 (xx)
KR (1) KR100884494B1 (xx)
CN (2) CN1264839C (xx)
AR (1) AR035941A1 (xx)
AT (1) ATE508128T1 (xx)
AU (1) AU2002308231B2 (xx)
BR (1) BR0207886A (xx)
CA (1) CA2438524C (xx)
DE (1) DE60239924D1 (xx)
DK (1) DK1373261T3 (xx)
ES (1) ES2364926T3 (xx)
HK (2) HK1063784A1 (xx)
IL (2) IL157543A0 (xx)
MX (1) MXPA03008040A (xx)
MY (1) MY137083A (xx)
PL (1) PL207392B1 (xx)
RU (1) RU2281284C2 (xx)
SE (1) SE0100733D0 (xx)
TW (1) TWI228990B (xx)
WO (1) WO2002070516A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021969A2 (en) * 2002-09-05 2004-03-18 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
SE0400021D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
DE602004024584D1 (de) * 2004-01-08 2010-01-21 Medivir Ab Inhibitoren der nicht-nukleotidischen reversen transkriptase
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
PE20080069A1 (es) 2006-05-15 2008-02-22 Merck & Co Inc Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
EP3013798B1 (en) * 2013-06-28 2018-06-27 BeiGene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3013797B1 (en) 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015089842A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Novel tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA973885A (en) * 1969-08-22 1975-09-02 Universal Oil Products Company Vinylation of aromatic compounds
US3803175A (en) 1969-08-22 1974-04-09 Universal Oil Prod Co Preparation of coumarin compounds
US4931221A (en) * 1988-12-30 1990-06-05 Ppg Industries, Inc. Photochromic spiropyran compounds
IL102548A (en) 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
NZ273741A (en) 1993-08-24 2000-06-23 Medivir Ab Heterocyclically-substituted guanidine, urea and thiourea derivatives
HU228886B1 (en) * 1998-01-16 2013-06-28 Medivir Ab Antiviral compounds, process for producing them and pharmaceutical compositions containing them
US5998411A (en) 1998-03-17 1999-12-07 Hughes Institute Heterocyclic nonnucleoside inhibitors of reverse transcriptase
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6136335A (en) 1998-12-31 2000-10-24 Hughes Institute Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity
US7186736B1 (en) 1999-03-20 2007-03-06 Parker Hughes Institute NNI for treatment of multi-drug resistant HIV
US6469034B1 (en) 1999-06-23 2002-10-22 Parker Hughes Institute Cyclohexenyl-ethyl-thiourea compounds for inhibiting HIV reverse transcriptase
US6207688B1 (en) 1999-06-23 2001-03-27 Parker Hughes Institute Phenethyl-thiourea compounds and use
US6124324A (en) 1999-06-23 2000-09-26 Hughes Institute Thiophene-ethyl thiourea compounds and use

Also Published As

Publication number Publication date
ES2364926T3 (es) 2011-09-16
AU2002308231B2 (en) 2007-05-10
MY137083A (en) 2008-12-31
CN101081843B (zh) 2010-10-13
CA2438524A1 (en) 2002-09-12
JP2009102436A (ja) 2009-05-14
DE60239924D1 (de) 2011-06-16
RU2281284C2 (ru) 2006-08-10
KR100884494B1 (ko) 2009-02-18
EP1373261A2 (en) 2004-01-02
ATE508128T1 (de) 2011-05-15
US7405310B2 (en) 2008-07-29
DK1373261T3 (da) 2011-08-29
MXPA03008040A (es) 2004-05-24
PL207392B1 (pl) 2010-12-31
RU2003129513A (ru) 2005-03-20
JP2004529112A (ja) 2004-09-24
HK1063784A1 (en) 2005-01-14
IL157543A0 (en) 2004-03-28
WO2002070516A3 (en) 2003-02-06
CN1494545A (zh) 2004-05-05
US6894177B2 (en) 2005-05-17
PL364414A1 (en) 2004-12-13
US20030069224A1 (en) 2003-04-10
US20050240035A1 (en) 2005-10-27
CN1264839C (zh) 2006-07-19
AR035941A1 (es) 2004-07-28
TWI228990B (en) 2005-03-11
US6716850B2 (en) 2004-04-06
JP4463478B2 (ja) 2010-05-19
EP1373261B1 (en) 2011-05-04
BR0207886A (pt) 2004-08-17
KR20030086601A (ko) 2003-11-10
CN101081843A (zh) 2007-12-05
HK1111155A1 (en) 2008-08-01
IL157543A (en) 2010-11-30
WO2002070516A2 (en) 2002-09-12
US20030187266A1 (en) 2003-10-02
CA2438524C (en) 2011-11-29

Similar Documents

Publication Publication Date Title
BR0309557A (pt) Inibidores da transcriptase reversa não nucleosìdeos
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
ECSP045274A (es) N-aminoacetil-pirrolidina-2-carbonitrilosy su uso como inhibidores ddp-iv
RS50629B (sr) Amidni prolek gemcitabina, kompozicije i njihova primena
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1109219T1 (el) Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
CY1108649T1 (el) Υποκατεστημενα αρυλπυραζολια ως παρασιτοκτονα
SE0301653D0 (sv) Novel compounds
BRPI0513051A (pt) combinação de inibidores de transcriptase reversa e de protease anti-hiv
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
EA200601855A1 (ru) Гербицидоактивные 3-амино-2-тиометилбензоилпиразолы
SE0100733D0 (sv) Non-nucleoside reverse transcriptase inhibitors
SE0302304D0 (sv) Novel compounds
MXPA05009282A (es) Derivados de anilina sustituidos.
SE0300445D0 (sv) New combination
DK1248651T3 (da) Produkt omfattende en heterotrimer G-proteinsignaltransduktionshæmmer kombineret med et antihypertensivt middel til terapeutisk anvendelse i behandlingen af arteriel hypertension
DK1326838T3 (da) Nye krystalformer af en inhibitor af faktor xa
SG171472A1 (en) Substituted aniline derivatives
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
BR0314759A (pt) Derivados de pirazol
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern